Spirax Group plc (SPX) — Investment Research Note

Executive summary

Spirax Group is a UK-listed specialist engineer of thermal energy management and fluid technology solutions, with three Businesses — Steam Thermal Solutions (STS), Electric Thermal Solutions (ETS) and Watson-Marlow Fluid Technology Solutions (WMFTS) — selling mission-critical kit and solutions to industrial customers via a direct sales force of ~2,100 engineers across ~70 countries. The 2020-2026 period covers an exceptional COVID-vaccine-driven boom in WMFTS (2020-22), a sharp Biopharm destock plus Semicon downturn that compressed Group margin from 25.3% (2021) to 20.0% (2025), and a stabilisation back to mid-single-digit organic growth with margin progression underway 2025-03-11 FY24, 2026-03-10 FY25. The single most important point for valuation today is that the share price embeds an essentially fully-recovered margin and AI/decarbonisation premium narrative against historical Group margins in the 20% range; valuation discipline is the key issue.

Fair value estimate

• Methodology: forward P/E on adjusted EPS cross-checked against EV/EBITDA on FY26 estimates. Spirax has historically traded at a premium industrial multiple (25-35x) given its consistent compounding record. Given current Group margin sits at 20% versus the 22-23% medium-term target, with execution risk on operating leverage and a more cyclical near-term backdrop, I anchor to a 18-22x range on FY26E EPS.
• Key assumptions: FY26E adjusted EPS ~315p (mid-single-digit organic growth on 296.3p FY25 base, modest currency drag), ~73.7m diluted shares. Apply 18-22x → fair value range 5,670p – 6,930p per share 2026-03-10 FY25.
• Implied market cap range: £4,179m – £5,107m (mid £4,643m). Compared to disclosed £5,291.9m, the current price sits at the top end / above my range.
• Absolute upside/(downside): approximately -12% to mid-point (range -4% upside to -21% downside).

Sector context

• ICB Industrial Goods and Services — confirmed; specialist flow control / fluid handling / thermal management subsegment.
• Spirax sits above typical sector peers on quality (margin, ROIC 13.1%, cash conversion 89%) and broadly in line on growth, but valuation is consistently at the higher end of the peer set. Leverage is above the pre-acquisition (Vulcanic/Durex 2022) profile but conservative at 1.5x EBITDA.
• Listed peers: Halma, Rotork, IMI, Watts Water (US), Xylem (US).

Investment thesis (3 bullets)

1. Niche, mission-critical positions with proven pricing power and high MRO mix — ~85% of sales funded from customers' opex budgets (MRO/solution sales) underpinning resilience, with consistent ability to grow ahead of IP and protect margin via active price management through inflation 2025-08-12 H1 results; 2026-03-10 FY25.
2. Genuine AI-receiver pockets within ETS — Semicon WFE exposure through Thermocoax/Durex Industries (continuing strong growth in Semicon noted across 2025/26), datacentre OEM contract win for Process Heating and Heat Trace datacentre opportunities provide a real, quantifiable AI-related uplift, even if not the dominant value driver 2025-08-12 H1; 2026-05-13 trading update.
3. Margin recovery roadmap + restructuring savings reinvestment — £40m of annualised restructuring savings, ETS Ogden Medium Voltage capacity expansion, Biopharm orders growth >10%, and stated medium-term margin target of 22-23% provide a credible operational lever once the cycle normalises 2026-03-10 FY25.

Key risks (3 bullets)

1. Stretched valuation vs current operating performance — Group margin (20.0%) remains 270bps below 2021 peak and 200-300bps below medium-term target; the market is paying for a normalisation that requires sustained IP recovery and ETS operational delivery 2026-03-10 FY25.
2. Biopharm boom/bust risk re-emerging at WMFTS — the 2023 destock that drove a 43% adjusted operating profit decline in Watson-Marlow showed how violently the segment can swing; a similar over-build cycle around new biologics/AI-driven drug discovery investment cannot be ruled out 2024-03-07 FY23.
3. Cyclical Semicon exposure & macro/IP weakness — Global IP weakness persists (2025 IP only 2.1%, Q1 2026 IP 1.4%); customers continue to defer large project capex. Tariff uncertainty and China weakness in STS large projects remain headwinds — not disclosed but inferred from continued cautious commentary 2026-05-13 trading update; 2025-11-13 trading update.

Operating leverage

Spirax has moderate-to-meaningful operating leverage but not the multiple-of-profit type. Adjusted Group operating margin moved from 22.7% (2020) to 25.3% (2021) on a 17% organic sales jump, then back to 20.0% (2025) on slower growth and revenue investments — implying drop-through on incremental volume of roughly 30-40% at the Group level. WMFTS is the highest-leverage business (26.2% margin at scale, 160bps organic margin gain in 2025 on 6% organic growth) — reflecting fixed manufacturing footprint (BioPure Portsmouth, Devens MA) and high gross margins. ETS has the biggest potential incremental leverage from underutilised Ogden Medium Voltage capacity (16.2% margin vs WMFTS 26.2%) — a 10-20% revenue surprise in ETS would likely deliver 40-50% incremental drop-through given the new MV facility's largely fixed cost base. STS is the most mature; leverage is real but capped by reinvestment discipline. A 10-20% Group revenue beat above plan would plausibly add 25-45% to operating profit — meaningful but not in the "multiples of profit" pure-software category 2026-03-10 FY25; 2025-08-12 H1 2025.

Value-trap signals

None identified at structural level. The franchise, balance sheet, and cash conversion are intact. The risk is "expensive quality" rather than structural decline. Watch items (not value-trap signals per se): Group margin still 270bps off peak four years on; ROIC 13.1% in 2025 vs 22.0% in 2021; cyclical WMFTS recovery has been slower than initial 2024 guidance suggested.

Earnings vs expectations

The disclosed period spans (a) the 2021 boom in which all three Businesses materially beat expectations driven by exceptional COVID-related demand; (b) 2022 H2 / 2023 in which Spirax issued sequential guidance downgrades — the November 2023 update revised Group full-year guidance to "lower 1-2% versus 2022 pro-forma" against original mid-single-digit growth, then 2024 H1 results were "slightly below expectations" with IP forecasts revised down repeatedly; (c) 2025 in which the company has consistently delivered in line with reiterated guidance at every trading update (May, August, November 2025; March 2026 FY; May 2026 update). The pattern is: outperforms in upcycles, misses sharply when the Biopharm/Semicon cycle turns down, and currently mid-cycle delivering as guided. Management's recent guidance discipline has been notably more conservative.

Conviction

Conviction: 4 (high).

• Anchored by: clean, well-audited financials with consistent restructuring/adjusting-item disclosure; multiple valuation cross-checks (forward P/E and EV/EBITDA) land in similar zone; the business model and unit economics are well-understood with a long track record.
• Limited by: terminal multiple assumption is the biggest variable — applying a high-quality compounder multiple (25-30x) versus a more cyclical industrial multiple (15-18x) shifts the answer materially; ETS/Semicon AI exposure is real but small enough that re-rating depends on broader sentiment rather than disclosed financials.

Driver scoring rationale (summary)

• ai_beneficiary 45: Semicon WFE through Thermocoax/Durex (~11% of ETS sales), datacentre OEM contract, Heat Trace for datacentres — real but minority of Group; not a dominant driver.
• operating_leverage 55: meaningful at WMFTS and at ETS Ogden ramp; Group blended is typical industrial.
• earnings_surprise_trend 45: more misses than beats over the 2022-24 cycle; back to in-line in 2025.
• cyclicality 55: industrial exposure tempered by 85% opex-funded sales but Biopharm/Semicon cycles have been violent.
• moat 65: direct sales + technical expertise + installed base — durable but execution-led, not network/regulatory.
• leverage 32: 1.5x net debt/EBITDA, BBB-equivalent profile, fortress-adjacent but not net cash.
• earnings_quality 75: 89% cash conversion, clean adjusting items, no aggressive accounting.
• management_quality 72: 56-year dividend record, disciplined M&A integration (Vulcanic/Durex), new CEO executing strategy refresh.
• growth_momentum 55: mid-single-digit organic growth running well ahead of IP; not accelerating dramatically.